Sei Investments Co. Sells 14,456 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Sei Investments Co. reduced its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 60.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,326 shares of the company’s stock after selling 14,456 shares during the period. Sei Investments Co.’s holdings in NewAmsterdam Pharma were worth $240,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in NAMS. American Century Companies Inc. bought a new position in NewAmsterdam Pharma in the 4th quarter worth about $8,907,000. DCF Advisers LLC grew its holdings in shares of NewAmsterdam Pharma by 162.9% during the fourth quarter. DCF Advisers LLC now owns 89,400 shares of the company’s stock worth $2,298,000 after purchasing an additional 55,400 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $276,000. Swiss National Bank increased its position in shares of NewAmsterdam Pharma by 105.1% in the fourth quarter. Swiss National Bank now owns 72,000 shares of the company’s stock worth $1,850,000 after purchasing an additional 36,900 shares during the last quarter. Finally, Keybank National Association OH bought a new stake in NewAmsterdam Pharma during the fourth quarter valued at approximately $257,000. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Up 1.5 %

NewAmsterdam Pharma stock opened at $15.12 on Friday. The firm has a fifty day simple moving average of $20.26 and a two-hundred day simple moving average of $21.26. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $27.29. The company has a market capitalization of $1.66 billion, a PE ratio of -5.82 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to analysts’ expectations of $3.30 million. As a group, equities analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on NAMS shares. Scotiabank increased their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 27th. Royal Bank of Canada reissued an “outperform” rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Needham & Company LLC reaffirmed a “buy” rating and set a $42.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Finally, UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a report on Monday, March 3rd. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $43.33.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now owns 15,000 shares of the company’s stock, valued at $305,550. This trade represents a 90.91 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James N. Topper acquired 1,135 shares of the firm’s stock in a transaction on Wednesday, March 26th. The stock was purchased at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the transaction, the director now directly owns 3,013,569 shares of the company’s stock, valued at approximately $67,775,166.81. This trade represents a 0.04 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.